M. Abdalla, Ireneous N. Soyiri, S. Atkin, T. Sathyapalan
{"title":"Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials","authors":"M. Abdalla, Ireneous N. Soyiri, S. Atkin, T. Sathyapalan","doi":"10.4103/jod.jod_16_23","DOIUrl":"https://doi.org/10.4103/jod.jod_16_23","url":null,"abstract":"","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79224634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ashish S. Dengra, Jigyasa Dengra, F. Farishta, Ramchandani Gd
{"title":"Papular lesions in a diabetic patient with COVID-19: A case report from India","authors":"Ashish S. Dengra, Jigyasa Dengra, F. Farishta, Ramchandani Gd","doi":"10.4103/jod.jod_70_22","DOIUrl":"https://doi.org/10.4103/jod.jod_70_22","url":null,"abstract":"","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77218853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rakesh M Parikh, Banshi Saboo, Viswanathan Mohan, Abdul Basit, Amit Gupta, Jayant K Panda, Mithun Bhartia, Pinar Topsever
The intricate relationship between the gut and the brain has long captured the imagination of scientists, philosophers, and clinicians alike. Over the past few decades, research has unveiled a complex and bidirectional communication network that connects these seemingly distinct organs, giving rise to the concept of the gut–brain axis. This axis represents a dynamic and multifaceted system through which the gut and the brain exchange signals, impacting not only digestive processes but also a wide array of physiological and neurological functions. From influencing appetite and mood to playing a role in metabolic regulation, the gut–brain axis has emerged as a crucial nexus in understanding human health and well-being. This chapter delves into the intricate mechanisms that underlie the gut–brain axis, exploring its components and pathways with a special focus on the role played by glucagon. By unraveling the mysteries of this axis, we gain valuable insights into how our body’s diverse systems collaborate to maintain a delicate balance and how disturbances within this axis can contribute to a range of health conditions.
{"title":"Glucagon in the gut – brain axis","authors":"Rakesh M Parikh, Banshi Saboo, Viswanathan Mohan, Abdul Basit, Amit Gupta, Jayant K Panda, Mithun Bhartia, Pinar Topsever","doi":"10.4103/jod.jod_103_23","DOIUrl":"https://doi.org/10.4103/jod.jod_103_23","url":null,"abstract":"The intricate relationship between the gut and the brain has long captured the imagination of scientists, philosophers, and clinicians alike. Over the past few decades, research has unveiled a complex and bidirectional communication network that connects these seemingly distinct organs, giving rise to the concept of the gut–brain axis. This axis represents a dynamic and multifaceted system through which the gut and the brain exchange signals, impacting not only digestive processes but also a wide array of physiological and neurological functions. From influencing appetite and mood to playing a role in metabolic regulation, the gut–brain axis has emerged as a crucial nexus in understanding human health and well-being. This chapter delves into the intricate mechanisms that underlie the gut–brain axis, exploring its components and pathways with a special focus on the role played by glucagon. By unraveling the mysteries of this axis, we gain valuable insights into how our body’s diverse systems collaborate to maintain a delicate balance and how disturbances within this axis can contribute to a range of health conditions.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135662400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dear Editor, Prof. M. Viswanathan (Prof. MV) was not just a doyen in the field of diabetes but also an astute clinician, teacher, researcher, and administrator. He made substantial contributions to diabetes care and research for nearly five decades. He was one of the most internationally recognized research scientists in India of his time. Prof. MV published more than 250 peer-reviewed research papers in prestigious national and international journals. His work propelled India to the forefront of diabetes care and research, and he played a pivotal role in elevating the nation’s status in this field. Born on August 26, 1923, in Kerala, India to Mr. A. K. Menon and Dr. M. Madhavi Amma (who was one of the first doctors of Kerala), Prof. MV’s career in medicine was greatly influenced by his mother. He pursued medicine at Stanley Medical College, Madras graduating in 1946, and worked as a House Physician. At a time, when diabetes was not regarded as a special field of study, he established the first organized diabetes clinic in India in 1948 at the Stanley Medical College. His dedication led to his promotion as Hon. Asst. Prof of Medicine and later as Hon. Prof of Medicine at the same college. In 1952, he married Sarada, who provided unwavering support throughout his life. Prof. MV voluntarily left government service with a view to setting up a hospital and research center devoted to clinical research in diabetes, the first of its kind in India. He also built up his private practice as a full-time Diabetologist. His achievements include the prestigious Dr.B.C.Roy National Award in 1982 for the development of the specialty of diabetology in India by the Medical Council of India. He has the unique honor of being the organizing secretary of three successive Association of Physicians of India (API) conferences. He held the posts of President, Association of Physicians of India, and President of the Scientific Section of the Diabetes Association of India with great distinction. He was also a member of the American Diabetes Association, British Diabetic Association, International Diabetes Federation, European Association for Study of Diabetes (EASD), and the Research Society for Study of Diabetes in India (RSSDI). At his center, Prof. MV created a modern reference library with well-organized resources for diabetes education and research. He also maintained a unique medical records system which served as a database for most of his long-term research findings. Many institutions sought his guidance in setting up modern and well-organized record-keeping departments. Prof. MV research efforts garnered numerous national and international honors and awards. He organized scientific conferences in India and also presented his research work at seminars and conferences worldwide. His primary objectives were to ensure high-quality diabetes research in India and more importantly to prevent and conquer diabetes. He pursued these goals relentlessly and with a missionary z
尊敬的编辑:M. Viswanathan教授(Prof. MV)不仅是糖尿病领域的元老,也是一位精明的临床医生、教师、研究员和管理者。在近50年的时间里,他为糖尿病的治疗和研究做出了重大贡献。他是当时印度最受国际认可的研究科学家之一。他在国内外知名期刊上发表了250多篇经同行评议的研究论文。他的工作将印度推向了糖尿病护理和研究的前沿,他在提升印度在这一领域的地位方面发挥了关键作用。梅农于1923年8月26日出生在印度喀拉拉邦,父母是A. K. Menon先生和M. Madhavi Amma博士(他是喀拉拉邦最早的医生之一)。他在马德拉斯斯坦利医学院攻读医学,1946年毕业,并担任住院医生。当时,糖尿病还没有被视为一个特殊的研究领域,他于1948年在斯坦利医学院建立了印度第一个有组织的糖尿病诊所。他的奉献精神使他晋升为荣誉助理医学教授,后来又成为同一所学院的荣誉医学教授。1952年,他与萨拉达结婚,萨拉达在他的一生中给予了他坚定的支持。MV教授自愿离开政府部门,成立了一家医院和研究中心,致力于糖尿病的临床研究,这是印度第一家此类医院。他还建立了自己的私人诊所,成为一名全职糖尿病专家。他的成就包括1982年由印度医学委员会颁发的著名的b.c. roy博士国家奖,以表彰他在印度糖尿病专科的发展。他有幸连续三次担任印度医师协会(API)会议的组织秘书。他曾担任印度医师协会主席和印度糖尿病协会科学分会主席,并取得了巨大的成就。他也是美国糖尿病协会、英国糖尿病协会、国际糖尿病联合会、欧洲糖尿病研究协会(EASD)和印度糖尿病研究学会(RSSDI)的成员。在他的中心,MV教授创建了一个现代化的参考图书馆,其中有组织良好的糖尿病教育和研究资源。他还拥有一个独特的医疗记录系统,作为他大部分长期研究成果的数据库。许多机构寻求他的指导,建立了现代化和组织良好的记录部门。他的研究工作获得了许多国家和国际上的荣誉和奖项。他在印度组织了科学会议,并在世界各地的研讨会和会议上介绍了他的研究工作。他的主要目标是确保印度高质量的糖尿病研究,更重要的是预防和征服糖尿病。直到1996年3月1日去世,他一直坚持不懈地追求这些目标。在印度,MV教授被公认并最终被称为“糖尿病学之父”。M. Viswanathan教授的研究历程在2型糖尿病的自然历史中,大多数个体都经历了一个葡萄糖调节受损的阶段,最终发展为糖尿病。1954年,Fajans和Conn首次将“糖尿病前期状态”确定为2型糖尿病的前兆。[1]他们将可的松GTT描述为一种检测糖尿病前期状态的可能方法。[2]早在1959年,MV教授就开始了这方面的研究工作。1962年,一项精心设计的研究聚焦于糖尿病患者的亲属,将他们与没有亲属患有糖尿病的对照组进行比较,在类固醇给药后对他们进行葡萄糖耐量试验,结果显示有糖尿病家族史的人,特别是30岁以下的人,血糖异常反应更高。该研究还考虑了肥胖的影响,并将研究结果与1954年至1961年的西方文献进行了比较。这项研究开创了一种识别未来糖尿病风险个体的方法,最终指导MV教授的糖尿病预防工作。[3]MV教授坚信糖尿病是可以预防的,并强调了个人和社区预防策略的重要性。他强调了糖尿病的基本风险因素,这些因素最终导致糖尿病的发展。遗传被确定为一个关键的风险因素,重点关注糖尿病患者的近亲和后代。与遗传因素相比,环境因素是可以改变的,它起着关键作用。其他风险因素,如肥胖、重复怀孕、缺乏体育活动和压力也得到了解决。筛查高危人群可以采取有效的预防措施。 他的观察结果使他相信预防糖尿病的必要性,并探索了阻止这一病理过程进展的方法和手段。[4-6]他强调需要通过初级预防努力认识和扭转糖尿病的自然历史。对后代荷尔蒙谱的研究提供了非常有趣和有用的信息。研究结果揭示了β细胞活性的早期异常。20世纪80年代初,他对胰岛素和c肽水平的研究为以后的研究奠定了基础。这些水平是在口服糖耐量试验中测量的,表明糖耐量受损(IGT)和糖尿病患者的β细胞功能降低,同时肝脏胰岛素提取减少。[7]其他研究人员在西方人群中也报告了类似的发现。1983年Rossell等[8]提出肥胖患者肝脏胰岛素提取减少。Bonora等[9]的另一项研究也表明,IGT中外周高胰岛素血症是胰腺分泌过多和肝脏胰岛素提取减少的结果。MV教授关于预防方面的最后一篇文章强调了减肥对于维持正常葡萄糖耐量的重要性,即使对于有强烈糖尿病家族史的非肥胖个体也是如此。他强调了体育锻炼和合理饮食在降低糖尿病风险方面的作用。[10]MV教授在倡导2型糖尿病预防方面远远领先于他的时代,甚至在NDDG和WHO定义IGT之前,就在葡萄糖耐受不良的早期迹象中提倡生活方式干预。MV教授的开创性研究彻底改变了糖尿病的营养研究。印度人的饮食以谷物为主,富含碳水化合物。当时在印度,人们认为糖尿病患者应该完全不吃米饭。MV教授发现,许多患者不能长期坚持规定的饮食改变。因此,他提出了限制卡路里高碳水化合物高纤维饮食(HCHF)的概念,允许患者遵循他们通常的饮食模式,以达到更好的饮食依从性和患者合作,但限制和避免游离糖。他证明了南印度人吃米饭但限制卡路里的饮食对糖尿病患者来说是理想的。这是MV教授在糖尿病营养学研究方面的重大研究贡献。MV教授注意到我国人民的饮食缺乏蛋白质。他提倡在他们的饮食中加入豆类和豆类形式的植物蛋白来增加蛋白质。这不仅使食物更加均衡,而且在短时间内实现了血糖控制。他创新的饮食策略实现了血糖和血脂的控制,打破了之前的观念。这种饮食模式现在被认为是糖尿病患者更可行的饮食。MV教授广泛研究了2型糖尿病的家族聚集性,强调了遗传对疾病患病率的影响。[11]他早期的研究分析了4000名2型糖尿病患者的亲属数量和分类,发现33.9%的研究参与者有糖尿病家族史,突出了糖尿病的家族聚集性。MV教授的另一项研究涉及对2600名患有糖尿病的夫妻的研究。[12]该研究显示了开创性的结果:当父母双方都患有糖尿病时,近62%的后代有患糖尿病的风险,而当父母只有一方患有糖尿病时,这一风险为22%。他与英国研究人员合作进行了先进的复杂分离遗传分析,为确定印度人群中的糖尿病易感基因铺平了道路。这些观察结果对寻找与2型糖尿病发病机制有关的基因具有重要意义。糖尿病的缓解期可以定义为血糖水平恢复到正常水平并且不需要抗糖尿病治疗的时期。糖尿病缓解的概念最近得到了广泛的认可。因此,令人惊讶的是,MV教授早在1987年就认识到了“糖尿病缓解”的概念。[13]他的研究强调了生活方式改变和医疗干预在实现缓解中的作用,为糖尿病的自然历史提供了有价值的见解。总而言之,MV教授对糖尿病领域的深刻贡献至今仍然有效,他对糖尿病研究的远见卓识产生了持久的影响。他对初级预防、创新饮食干预以及家族聚集和临床管理的开创性研究的重视,极大地推动了该领域的发展,并有助于我们对糖尿病的理解。
{"title":"Prof. M. Viswanathan: The pride of Asia in diabetology","authors":"Satyavani Kumpatla, Vijay Viswanathan, Ambady Ramachandran, Viswanathan Mohan","doi":"10.4103/jod.jod_108_23","DOIUrl":"https://doi.org/10.4103/jod.jod_108_23","url":null,"abstract":"Dear Editor, Prof. M. Viswanathan (Prof. MV) was not just a doyen in the field of diabetes but also an astute clinician, teacher, researcher, and administrator. He made substantial contributions to diabetes care and research for nearly five decades. He was one of the most internationally recognized research scientists in India of his time. Prof. MV published more than 250 peer-reviewed research papers in prestigious national and international journals. His work propelled India to the forefront of diabetes care and research, and he played a pivotal role in elevating the nation’s status in this field. Born on August 26, 1923, in Kerala, India to Mr. A. K. Menon and Dr. M. Madhavi Amma (who was one of the first doctors of Kerala), Prof. MV’s career in medicine was greatly influenced by his mother. He pursued medicine at Stanley Medical College, Madras graduating in 1946, and worked as a House Physician. At a time, when diabetes was not regarded as a special field of study, he established the first organized diabetes clinic in India in 1948 at the Stanley Medical College. His dedication led to his promotion as Hon. Asst. Prof of Medicine and later as Hon. Prof of Medicine at the same college. In 1952, he married Sarada, who provided unwavering support throughout his life. Prof. MV voluntarily left government service with a view to setting up a hospital and research center devoted to clinical research in diabetes, the first of its kind in India. He also built up his private practice as a full-time Diabetologist. His achievements include the prestigious Dr.B.C.Roy National Award in 1982 for the development of the specialty of diabetology in India by the Medical Council of India. He has the unique honor of being the organizing secretary of three successive Association of Physicians of India (API) conferences. He held the posts of President, Association of Physicians of India, and President of the Scientific Section of the Diabetes Association of India with great distinction. He was also a member of the American Diabetes Association, British Diabetic Association, International Diabetes Federation, European Association for Study of Diabetes (EASD), and the Research Society for Study of Diabetes in India (RSSDI). At his center, Prof. MV created a modern reference library with well-organized resources for diabetes education and research. He also maintained a unique medical records system which served as a database for most of his long-term research findings. Many institutions sought his guidance in setting up modern and well-organized record-keeping departments. Prof. MV research efforts garnered numerous national and international honors and awards. He organized scientific conferences in India and also presented his research work at seminars and conferences worldwide. His primary objectives were to ensure high-quality diabetes research in India and more importantly to prevent and conquer diabetes. He pursued these goals relentlessly and with a missionary z","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135703814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Chavda, S. Jha, T. Gandhi, A. Patel, Hiren Raninga, Amol Chaudhari, D. Hasnani
Objective: The present study was aimed to evaluate effect of metabolic parameters on erectile dysfunction (ED) in individuals with type-2 diabetes mellitus (T2DM) and to assess the efficacy of Tadalafil and Tadalafil + Dapoxetine combination. Materials and Methods: A prospective, observational, cross-sectional, bicentric study included 216 males with T2DM who are not treated with phosphodiesterase 5 inhibitors and without chronic kidney disease. The data were obtained from demographic questionnaire, clinical laboratory reports of glycometabolic parameters namely body mass index (BMI), hemoglobin A1c (HbA1c), testosterone, vitamin B12 (VitB12), and lipid profile and analyses of the International Index of Erectile Function (IIEF) questionnaire. The effect of physical and metabolic parameters on IIEF sub-domains namely erectile function; orgasmic function; sexual desire (SD); intercourse satisfaction; and overall satisfaction was evaluated. A statistical significance was evaluated using χ2 test or t-test. Result: SD is most significantly lower in subjects with imbalanced physiological and metabolic characteristics including BMI, HbA1c, testosterone, VitB12, triglyceride, high-density lipoprotein, and low-density lipoprotein. Both Tadalafil and Tadalafil + Dapoxetine significantly improved almost all IIEF parameters without any pronounced effect of either. Similarly, both the treatments improved all the IIEF parameters for subjects with high BMI except for SD. In subjects with cardiac comorbidities, the use of either treatment significantly enhanced all the IIEF scores. Conclusion: The findings of this study outline the need of careful examination of sexual dysfunction in healthcare clinics for diabetic individuals. An imbalanced physiological and metabolic profile leads to ED in individuals with T2DM. Additionally, the presence of co-morbidities further elevates the odds of ED prevalence. The treatment with Tadalafil and Tadalafil + Dapoxetine drug combination shows promising results in improving the ED but a study with larger pool of subjects is needed to determine the additional benefits of Dapoxetine.
{"title":"The efficacy of Tadalafil and Tadalafil + Dapoxetine in managing sexual dysfunction in individuals with type-2 diabetes mellitus: A clinical study","authors":"V. Chavda, S. Jha, T. Gandhi, A. Patel, Hiren Raninga, Amol Chaudhari, D. Hasnani","doi":"10.4103/jod.jod_123_22","DOIUrl":"https://doi.org/10.4103/jod.jod_123_22","url":null,"abstract":"Objective: The present study was aimed to evaluate effect of metabolic parameters on erectile dysfunction (ED) in individuals with type-2 diabetes mellitus (T2DM) and to assess the efficacy of Tadalafil and Tadalafil + Dapoxetine combination. Materials and Methods: A prospective, observational, cross-sectional, bicentric study included 216 males with T2DM who are not treated with phosphodiesterase 5 inhibitors and without chronic kidney disease. The data were obtained from demographic questionnaire, clinical laboratory reports of glycometabolic parameters namely body mass index (BMI), hemoglobin A1c (HbA1c), testosterone, vitamin B12 (VitB12), and lipid profile and analyses of the International Index of Erectile Function (IIEF) questionnaire. The effect of physical and metabolic parameters on IIEF sub-domains namely erectile function; orgasmic function; sexual desire (SD); intercourse satisfaction; and overall satisfaction was evaluated. A statistical significance was evaluated using χ2 test or t-test. Result: SD is most significantly lower in subjects with imbalanced physiological and metabolic characteristics including BMI, HbA1c, testosterone, VitB12, triglyceride, high-density lipoprotein, and low-density lipoprotein. Both Tadalafil and Tadalafil + Dapoxetine significantly improved almost all IIEF parameters without any pronounced effect of either. Similarly, both the treatments improved all the IIEF parameters for subjects with high BMI except for SD. In subjects with cardiac comorbidities, the use of either treatment significantly enhanced all the IIEF scores. Conclusion: The findings of this study outline the need of careful examination of sexual dysfunction in healthcare clinics for diabetic individuals. An imbalanced physiological and metabolic profile leads to ED in individuals with T2DM. Additionally, the presence of co-morbidities further elevates the odds of ED prevalence. The treatment with Tadalafil and Tadalafil + Dapoxetine drug combination shows promising results in improving the ED but a study with larger pool of subjects is needed to determine the additional benefits of Dapoxetine.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"29 1","pages":"48 - 55"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87149416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Baldane, M. Çelik, M. Korez, Emine Gul Baldane, S. Abuşoğlu, Unlu Ali, S. Ipekci, L. Kebapçılar
Objective: This study was aimed to compare serum galectin-3 (Gal-3) levels in gestational diabetes mellitus (GDM) and healthy pregnant women and to evaluate the relationship between insulin resistance parameters and serum Gal-3 levels. Materials and Methods: Fifty-nine pregnant women who were screened for GDM with oral glucose tolerance tests (OGTT) at the 24th–28th gestational weeks were included in the study. According to the results of OGTT, 34 pregnant women were included in the GDM group and 25 pregnant women were included in the control group. Results: Serum Gal-3 value was found to be similar in the GDM and control group (P < 0.471). However, there was a significant positive association between Gal-3 and fasting insulin (r = 0.509, P < 0.001) and homeostasis model assessment of insulin resistance (HOMA-IR) (r = 0.479, P < 0.001) in the whole pregnancies, and between Gal-3 levels and fasting insulin (r = 0.608, P < 0.001), HOMA-IR (r = 0.609, P < 0.001), and OGTT 60 min glucose (r = 0.444, P = 0.016) in the GDM patients. Conclusions: There was no difference in the last trimester serum Gal-3 levels between GDM and healthy pregnant women. However, a significant positive correlation was determined between Gal-3 and fasting insulin, HOMA-IR, and OGTT 60 min glucose values in the GDM group, and fasting insulin and HOMA-IR values in whole pregnancies. The results of our study support previous data reporting the relationship between Gal-3 and GDM through insulin resistance.
目的:比较妊娠期糖尿病(GDM)与健康孕妇血清半乳糖凝集素-3 (Gal-3)水平,探讨胰岛素抵抗参数与血清Gal-3水平的关系。材料与方法:采用口服糖耐量试验(OGTT)筛查妊娠期24 ~ 28周GDM的59例孕妇纳入研究。根据OGTT结果,34名孕妇被纳入GDM组,25名孕妇被纳入对照组。结果:GDM组血清Gal-3值与对照组相似(P < 0.471)。然而,在整个妊娠期,Gal-3水平与空腹胰岛素(r = 0.509, P < 0.001)和胰岛素抵抗稳态模型评估(HOMA-IR) (r = 0.479, P < 0.001)呈显著正相关;在GDM患者中,Gal-3水平与空腹胰岛素(r = 0.608, P < 0.001)、HOMA-IR (r = 0.609, P < 0.001)和OGTT 60分钟葡萄糖(r = 0.444, P = 0.016)呈显著正相关。结论:妊娠晚期GDM与健康孕妇血清Gal-3水平无差异。然而,Gal-3与GDM组的空腹胰岛素、HOMA-IR和OGTT 60分钟血糖值以及全妊娠期的空腹胰岛素和HOMA-IR值之间存在显著的正相关。我们的研究结果支持了先前关于Gal-3通过胰岛素抵抗与GDM之间关系的报道。
{"title":"Assessment of serum galectin-3 levels in patients with gestational diabetes mellitus","authors":"S. Baldane, M. Çelik, M. Korez, Emine Gul Baldane, S. Abuşoğlu, Unlu Ali, S. Ipekci, L. Kebapçılar","doi":"10.4103/jod.jod_84_22","DOIUrl":"https://doi.org/10.4103/jod.jod_84_22","url":null,"abstract":"Objective: This study was aimed to compare serum galectin-3 (Gal-3) levels in gestational diabetes mellitus (GDM) and healthy pregnant women and to evaluate the relationship between insulin resistance parameters and serum Gal-3 levels. Materials and Methods: Fifty-nine pregnant women who were screened for GDM with oral glucose tolerance tests (OGTT) at the 24th–28th gestational weeks were included in the study. According to the results of OGTT, 34 pregnant women were included in the GDM group and 25 pregnant women were included in the control group. Results: Serum Gal-3 value was found to be similar in the GDM and control group (P < 0.471). However, there was a significant positive association between Gal-3 and fasting insulin (r = 0.509, P < 0.001) and homeostasis model assessment of insulin resistance (HOMA-IR) (r = 0.479, P < 0.001) in the whole pregnancies, and between Gal-3 levels and fasting insulin (r = 0.608, P < 0.001), HOMA-IR (r = 0.609, P < 0.001), and OGTT 60 min glucose (r = 0.444, P = 0.016) in the GDM patients. Conclusions: There was no difference in the last trimester serum Gal-3 levels between GDM and healthy pregnant women. However, a significant positive correlation was determined between Gal-3 and fasting insulin, HOMA-IR, and OGTT 60 min glucose values in the GDM group, and fasting insulin and HOMA-IR values in whole pregnancies. The results of our study support previous data reporting the relationship between Gal-3 and GDM through insulin resistance.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"55 1","pages":"28 - 33"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79254957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Shobana, Rajagopal Gayathri, Mathiyazhagan Jayanthan, V. Sudha, S. Jamdar, N. Malleshi, Kamala Krishnaswamy, Ranjit Mohan Anjana, R. Unnikrishnan, V. Mohan
Background: The nutritional importance of brown rice (BR) is well established. Despite several nutritional benefits of BR, its consumption remains limited due to long cooking time and limited shelf-life. BR can be subjected to processing to improve shelf-life. Gamma irradiation is one such strategy, but it could induce changes in the grain and thus affect its glycemic properties. Aims and objectives: The aim of this study was to look at the 24-h glycemic response of irradiated and non-irradiated BR-based iso-caloric diets in Asian Indians. Methods: Fifteen (mean body mass index: 24 ± 2.6 kg/m2) Asian Indian adults without diabetes, aged 25–39 years, participated in this randomized cross-over study. Iso-caloric diets were prepared with two varieties (ADT 43 and Swarna) of parboiled gamma-irradiated brown rice with 750–820 Gy dosage (IBR) and non-irradiated brown rice (NIBR). After the participants consumed these diets, 24-h glycemic responses were recorded using a continuous glucose monitoring system. The mean positive change from baseline glucose concentration was calculated as the incremental area under the curve (IAUC) for both the diets. Results: The percentage difference in 24-h average IAUC was 10% lower in the IBR diets when compared with NIBR diets, irrespective of the variety of BR (P = 0.56). In the case of ADT 43 rice variety, both IBR and NIBR diets showed similar IAUC (P = 0.68). However, the IBR of Swarna rice variety showed 21% lower IAUC when compared with the NIBR diet (P = 0.21). Comparing the IBR varieties, Swarna showed 21% lower IAUC than ADT 43 (P = 0.21), whereas between NIBR varieties, only 0.79% difference was observed between ADT 43 and Swarna (P = 0.93). Conclusions: Gamma irradiation of parboiled BR did not produce significant differences in the 24-h glycemic responses for BR-based diets. Swarna variety was better than ADT 43 with regard to glycemic response. Judicious application of radiation technology to BR varieties may help in shelf-life extension without affecting the glycemic properties.
{"title":"Effect of gamma irradiation on the 24-h glycemic responses of parboiled brown rice diets in Asian Indian adults: A randomized cross-over study","authors":"S. Shobana, Rajagopal Gayathri, Mathiyazhagan Jayanthan, V. Sudha, S. Jamdar, N. Malleshi, Kamala Krishnaswamy, Ranjit Mohan Anjana, R. Unnikrishnan, V. Mohan","doi":"10.4103/jod.jod_81_22","DOIUrl":"https://doi.org/10.4103/jod.jod_81_22","url":null,"abstract":"Background: The nutritional importance of brown rice (BR) is well established. Despite several nutritional benefits of BR, its consumption remains limited due to long cooking time and limited shelf-life. BR can be subjected to processing to improve shelf-life. Gamma irradiation is one such strategy, but it could induce changes in the grain and thus affect its glycemic properties. Aims and objectives: The aim of this study was to look at the 24-h glycemic response of irradiated and non-irradiated BR-based iso-caloric diets in Asian Indians. Methods: Fifteen (mean body mass index: 24 ± 2.6 kg/m2) Asian Indian adults without diabetes, aged 25–39 years, participated in this randomized cross-over study. Iso-caloric diets were prepared with two varieties (ADT 43 and Swarna) of parboiled gamma-irradiated brown rice with 750–820 Gy dosage (IBR) and non-irradiated brown rice (NIBR). After the participants consumed these diets, 24-h glycemic responses were recorded using a continuous glucose monitoring system. The mean positive change from baseline glucose concentration was calculated as the incremental area under the curve (IAUC) for both the diets. Results: The percentage difference in 24-h average IAUC was 10% lower in the IBR diets when compared with NIBR diets, irrespective of the variety of BR (P = 0.56). In the case of ADT 43 rice variety, both IBR and NIBR diets showed similar IAUC (P = 0.68). However, the IBR of Swarna rice variety showed 21% lower IAUC when compared with the NIBR diet (P = 0.21). Comparing the IBR varieties, Swarna showed 21% lower IAUC than ADT 43 (P = 0.21), whereas between NIBR varieties, only 0.79% difference was observed between ADT 43 and Swarna (P = 0.93). Conclusions: Gamma irradiation of parboiled BR did not produce significant differences in the 24-h glycemic responses for BR-based diets. Swarna variety was better than ADT 43 with regard to glycemic response. Judicious application of radiation technology to BR varieties may help in shelf-life extension without affecting the glycemic properties.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"43 1 1","pages":"20 - 27"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76914413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Health literacy, medication belief, and demographic factors as correlates of medication adherence in person with diabetes mellitus","authors":"O. Olorunfemi","doi":"10.4103/jod.jod_4_23","DOIUrl":"https://doi.org/10.4103/jod.jod_4_23","url":null,"abstract":"","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88293819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Debashish Brahmachari, Shabeen Naz Masood, Umaira Aziz, Tatjana Milenkovic, Manoj Chawla, A G Unnikrishnan, Sujoy Ghosh, João Raposo, Banshi Saboo, Viswanathan Mohan
Abstract This review article looks at the historical journey of the discovery of glucagon and the initial stages of research that paved the way for a comprehensive understanding of its physiological significance. Glucagon, an essential peptide hormone produced by the pancreas, plays a pivotal role in maintaining glucose homeostasis. Tracing the trajectory of its discovery from its initial identification to the unraveling of its complex functions, this article offers a detailed analysis of the early scientific endeavors, and collaborations that contributed to shaping our understanding of glucagon’s pivotal role. By exploring the historical context, controversies, and advancements, this review sheds light on the evolution of endocrinological knowledge and its profound implications for diabetes research and treatment strategies.
{"title":"Historical perspectives of glucagon’s discovery and early research","authors":"Debashish Brahmachari, Shabeen Naz Masood, Umaira Aziz, Tatjana Milenkovic, Manoj Chawla, A G Unnikrishnan, Sujoy Ghosh, João Raposo, Banshi Saboo, Viswanathan Mohan","doi":"10.4103/jod.jod_107_23","DOIUrl":"https://doi.org/10.4103/jod.jod_107_23","url":null,"abstract":"Abstract This review article looks at the historical journey of the discovery of glucagon and the initial stages of research that paved the way for a comprehensive understanding of its physiological significance. Glucagon, an essential peptide hormone produced by the pancreas, plays a pivotal role in maintaining glucose homeostasis. Tracing the trajectory of its discovery from its initial identification to the unraveling of its complex functions, this article offers a detailed analysis of the early scientific endeavors, and collaborations that contributed to shaping our understanding of glucagon’s pivotal role. By exploring the historical context, controversies, and advancements, this review sheds light on the evolution of endocrinological knowledge and its profound implications for diabetes research and treatment strategies.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135703807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Banshi Saboo, Akhtar Hussain, Abdul Basit, Viswanathan Mohan
Dear Editor, We are very happy to present a special issue of the Journal of Diabetology (JOD) which is dedicated to the centenary celebrations of two major events. The year 2023 marks the birth centenary of Prof. M. Viswanathan, considered the “Father of Diabetology in India.” 2023 also marks the centenary of the discovery of the enigmatic hormone, glucagon. To mark these two very special occasions, JOD is proud to present a special tribute to Prof. M. Viswanathan, written by his two sons, Dr. V. Mohan and Dr. Vijay Viswanathan, and his son-in-law, Dr. A. Ramachandran, all of whom were personally mentored by Prof. M. Viswanathan. We dedicate this issue to Prof. M. Viswanathan whose contributions are legendary. He is credited with starting the specialty of Diabetology in India. This year also marks the centenary of the discovery of glucagon, the pancreatic hormone produced by the alpha cells of the islets of Langerhans. To commemorate the centenary of glucagon, we invited specialists from different parts of the world to contribute articles for a special issue dedicated to glucagon. This includes historical aspects, including its discovery, and goes on to describe its increasing role today in the management of both diabetes and obesity. We are very grateful to the authors who have contributed articles for the special issue of JOD at short notice. We do hope you will enjoy reading about this oft-forgotten, but important, hormone, glucagon. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
{"title":"Centenary of glucagon discovery and birth centenary of a pioneer in diabetology in India","authors":"Banshi Saboo, Akhtar Hussain, Abdul Basit, Viswanathan Mohan","doi":"10.4103/jod.jod_109_23","DOIUrl":"https://doi.org/10.4103/jod.jod_109_23","url":null,"abstract":"Dear Editor, We are very happy to present a special issue of the Journal of Diabetology (JOD) which is dedicated to the centenary celebrations of two major events. The year 2023 marks the birth centenary of Prof. M. Viswanathan, considered the “Father of Diabetology in India.” 2023 also marks the centenary of the discovery of the enigmatic hormone, glucagon. To mark these two very special occasions, JOD is proud to present a special tribute to Prof. M. Viswanathan, written by his two sons, Dr. V. Mohan and Dr. Vijay Viswanathan, and his son-in-law, Dr. A. Ramachandran, all of whom were personally mentored by Prof. M. Viswanathan. We dedicate this issue to Prof. M. Viswanathan whose contributions are legendary. He is credited with starting the specialty of Diabetology in India. This year also marks the centenary of the discovery of glucagon, the pancreatic hormone produced by the alpha cells of the islets of Langerhans. To commemorate the centenary of glucagon, we invited specialists from different parts of the world to contribute articles for a special issue dedicated to glucagon. This includes historical aspects, including its discovery, and goes on to describe its increasing role today in the management of both diabetes and obesity. We are very grateful to the authors who have contributed articles for the special issue of JOD at short notice. We do hope you will enjoy reading about this oft-forgotten, but important, hormone, glucagon. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135703811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}